Skip to content

Concentration of S-1 Metabolites in Tear and Plasma of Patients Receiving TS-1

Concentration of S-1 Metabolites in Tear and Plasma and Correlation With Its Side Effects in Patients Receiving S-1 Adjuvant Chemotherapy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01621919
Enrollment
200
Registered
2012-06-18
Start date
2010-12-31
Completion date
2013-05-31
Last updated
2012-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

S-1 has been also shown to be an effective drug for palliative chemotherapy in Eastern and Western GC patients. Recently, some case and small-sized studies have been reported on lacrimal drainage obstruction(LDO)caused by S-1.Suggested mechanism of LDO involves direct secretion of S-1 into the tear; thus the concentration of S-1 metabolite in tear is expected to be high in patients who developed LDO than in patients without LDO. We investigate the concentration of S-1 and its metabolites in tear and plasma and find out its correlation with side effects such as LDO. These results will also help us identify patients who are at high risk of developing S-1-associated side effects.

Detailed description

1. S-1 metabolites concentration in plasma 1. factors affecting plasma concentration * surgery subtype * serum creatinine 2. systemic adverse effects of S-1 and its correlation with plasma S-1 metabolites concentration * enteritis * fatigue 2. S-1 metabolites concentration in tears 1. correlation of tear concentration with plasma concentration 2. lacrimal drainage obstruction caused by S-1 administration, and its correlation with tear S-1 metabolites concentration 3. lacrimal drainage obstruction caused by S-1 administration, and its correlation with plasma S-1 metabolites concentration

Interventions

None listed

Sponsors

Seoul National University Bundang Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients who received radical surgery for gastric cancer * Patients who receiving S-1 adjuvant chemotherapy * Patients who administrated S-1 for more than 7 days

Exclusion criteria

* who using eyedrop medication * who has dry eye that tear cannot be sampled

Countries

South Korea

Contacts

Primary ContactKeon-Wook Lee, MD
hmodocto@hanmail.net82-31-787-7073

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026